Literature DB >> 30861094

Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?

Esten N Vandsemb1,2,3, Tae Kon Kim1, Amer M Zeidan1.   

Abstract

Entities:  

Keywords:  AML; acute myeloid leukemia; bone marrow; immune checkpoint blockade; immunotherapy

Mesh：

Substances：

Year:  2019        PMID： 30861094      PMCID： PMC6467744          DOI： 10.1002/cncr.32042

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  9 in total

1.  Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.

Authors:  Seng-Ryong Woo; Meghan E Turnis; Monica V Goldberg; Jaishree Bankoti; Mark Selby; Christopher J Nirschl; Matthew L Bettini; David M Gravano; Peter Vogel; Chih Long Liu; Stephanie Tangsombatvisit; Joseph F Grosso; George Netto; Matthew P Smeltzer; Alcides Chaux; Paul J Utz; Creg J Workman; Drew M Pardoll; Alan J Korman; Charles G Drake; Dario A A Vignali
Journal:  Cancer Res       Date:  2011-12-20       Impact factor: 12.701

2.  Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.

Authors:  Christopher G Kanakry; Allan D Hess; Christopher D Gocke; Christopher Thoburn; Ferdynand Kos; Christian Meyer; Janet Briel; Leo Luznik; B Douglas Smith; Hyam Levitsky; Judith E Karp
Journal:  Blood       Date:  2010-10-08       Impact factor: 22.113

3.  Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.

Authors:  Qing Zhou; Meghan E Munger; Rachelle G Veenstra; Brenda J Weigel; Mitsuomi Hirashima; David H Munn; William J Murphy; Miyuki Azuma; Ana C Anderson; Vijay K Kuchroo; Bruce R Blazar
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

Review 4.  Molecular and cellular insights into T cell exhaustion.

Authors:  E John Wherry; Makoto Kurachi
Journal:  Nat Rev Immunol       Date:  2015-08       Impact factor: 53.106

5.  Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.

Authors:  Raanan Berger; Rinat Rotem-Yehudar; Gideon Slama; Shimon Landes; Abraham Kneller; Merav Leiba; Maya Koren-Michowitz; Avichai Shimoni; Arnon Nagler
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

6.  Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.

Authors:  Hanna A Knaus; Sofia Berglund; Hubert Hackl; Amanda L Blackford; Joshua F Zeidner; Raúl Montiel-Esparza; Rupkatha Mukhopadhyay; Katrina Vanura; Bruce R Blazar; Judith E Karp; Leo Luznik; Ivana Gojo
Journal:  JCI Insight       Date:  2018-11-02

7.  A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.

Authors:  Amer M Zeidan; Hanna A Knaus; Tara M Robinson; Andrea M H Towlerton; Edus H Warren; Joshua F Zeidner; Amanda L Blackford; Amy S Duffield; David Rizzieri; Mark G Frattini; Yair M Levy; Mark A Schroeder; Anna Ferguson; Katherine E Sheldon; Amy E DeZern; Ivana Gojo; Steven D Gore; Howard Streicher; Leo Luznik; B Douglas Smith
Journal:  Clin Cancer Res       Date:  2018-05-01       Impact factor: 12.531

Review 8.  Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.

Authors:  Olumide Babajide Gbolahan; Amer M Zeidan; Maximilian Stahl; Mohammad Abu Zaid; Sherif Farag; Sophie Paczesny; Heiko Konig
Journal:  Int J Mol Sci       Date:  2017-07-31       Impact factor: 5.923

9.  PDL1 Regulation by p53 via miR-34.

Authors:  Maria Angelica Cortez; Cristina Ivan; David Valdecanas; Xiaohong Wang; Heidi J Peltier; Yuping Ye; Luiz Araujo; David P Carbone; Konstantin Shilo; Dipak K Giri; Kevin Kelnar; Desiree Martin; Ritsuko Komaki; Daniel R Gomez; Sunil Krishnan; George A Calin; Andreas G Bader; James W Welsh
Journal:  J Natl Cancer Inst       Date:  2015-11-17       Impact factor: 13.506
  9 in total
  3 in total

Review 1.  A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia.

Authors:  Seyed Mohammadreza Bolandi; Mahdi Pakjoo; Peyman Beigi; Mohammad Kiani; Ali Allahgholipour; Negar Goudarzi; Jamshid S Khorashad; Anna M Eiring
Journal:  Cells       Date:  2021-10-21       Impact factor: 6.600

2.  A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.

Authors:  Amer M Zeidan; Isaac Boss; C L Beach; Wilbert B Copeland; Ethan Thompson; Brian A Fox; Vanessa E Hasle; Ken Ogasawara; James Cavenagh; Lewis R Silverman; Maria Teresa Voso; Andrzej Hellmann; Mar Tormo; Tim O'Connor; Alessandro Previtali; Shelonitda Rose; Guillermo Garcia-Manero
Journal:  Blood Adv       Date:  2022-04-12

3.  Identification of prognostic genes and construction of a novel gene signature in the skin melanoma based on the tumor microenvironment.

Authors:  Wang Yingjuan; Zhang Li; Cao Wei; Wang Xiaoyuan
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.